A multidrug resistance transporter from human MCF-7 breast cancer cells
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent reduction in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein. RNA fingerprinting led to the identification of a 2.4-kb mRNA that is overexpressed in MCF-7/AdrVp cells relative to parental MCF-7 cells. The mRNA encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that we term breast cancer resistance protein (BCRP). Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells. BCRP is a xenobiotic transporter that appears to play a major role in the multidrug resistance phenotype of MCF-7/AdrVp human breast cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Current protocols in molecular biology
Sargent, T. (1988) · Analytical Biochemistry · doi:10.1016/0003-2697(88)90147-9 · Cited by 7,205
Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01276.x · Cited by 5,312
Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction
Liang, P., & Pardee, A. B. (1992) · Science · doi:10.1126/science.1354393 · Cited by 4,984
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Isolation and expression of a complementary DNA that confers multidrug resistance
Gros, P., Neriah, Y. B., Croop, J. M., & Housman, D. E. (1986) · Nature · doi:10.1038/323728a0 · Cited by 797
Biedler, J. L., & Riehm, H. (1970) · PubMed · Cited by 747
Reduced permeability in CHO cells as a mechanism of resistance to colchicine
Ling, V., & Thompson, L. H. (1974) · Journal of Cellular Physiology · doi:10.1002/jcp.1040830114 · Cited by 686
Sex Limited Inheritance in Drosophila
Morgan, T. H. (1910) · Science · doi:10.1126/science.32.812.120 · Cited by 616
Sex-linked inheritance in Drosophila
Morgan, T. H., & Bridges, C. B. (1916) · Carnegie Institution of Washington eBooks · doi:10.5962/bhl.title.54326 · Cited by 589
Research works printed but not linked: 12
- D Kessel, V Botterill, I Wodinsky Cancer Res 28, 938–941 (1968).
- J L Biedler, H Riehm Cancer Res 30, 1174–1184 (1970).
- J S Lee, S Scala, Y Matsumoto, B Dickstein, R Robey, Z Zhan, G Altenberg, S E Bates J Cell Biochem 65, 513–526 (1997). · doi:10.1002/(sici)1097-4644(19970615)65:4<513::aid-jcb7>3.0.co;2-r
- L A Doyle, D D Ross, R Sridhara, A T Fojo, S H Kaufmann, E J Lee, C A Schiffer Br J Cancer 71, 52–58 (1995). · doi:10.1038/bjc.1995.11
- P Liang, L Averboukh, K Keyomarsi, R Sager, A Pardee Cancer Res 52, 6966–6968 (1992).
- D D Ross, L A Doyle, C A Schiffer, E J Lee, C E Grant, S P C Cole, R G Deeley, W Yang, Y Tong Leukemia 10, 48–55 (1996).
- P M Bingham, R Levis, G M Rubin Cell 25, 693–704 (1981). · doi:10.1016/0092-8674(81)90176-8
- H Chen, C Rossier, M D Lalioti, A Lynn, A Chakravarti, G Perrin, S E Antonarkis Am J Hum Genet 59, 66–75 (1996).
- E L Pugh, S J Wakil J Biol Chem 240, 4727–4733 (1965). · doi:10.1016/s0021-9258(18)97016-x
- J K M Rao, P Garos Biochim Biophys Acta 899, 179–214 (1986).
- D D Ross, Y Gao, Y Yang, J Leszyk, J Shively, L A Doyle Cancer Res 57, 5460–5464 (1997).
- H Kawaharata, Y Hinoda, F Itoh, T Endo, S Oikawa, H Nakazato, K Imai Int J Cancer 72, 377–382 (1997). · doi:10.1002/(sici)1097-0215(19970717)72:2<377::aid-ijc29>3.0.co;2-b
Cited by
Items 101–200 of 209
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function
Fung, K. L., & Gottesman, M. M. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.02.014 · Cited by 335
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance
Wang, H., Gao, Z., Liu, X., Agarwal, P., Zhao, S., Conroy, D. W., Ji, G., Yu, J., Jaroniec, C. P., Liu, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02915-8 · Cited by 331
RetractedBreedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323
Houghton, P. J., Germain, G. S., Harwood, F. C., Schuetz, J. D., Stewart, C. F., Buchdunger, E., & Traxler, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3344 · Cited by 323
ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy
Ding, X.-W., Wu, J.-H., & Jiang, C.-P. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.02.012 · Cited by 323
Mechanisms of Resistance to Photodynamic Therapy
Casas, A., Di Venosa, G., Hasan, T., & Batlle, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843272 · Cited by 322
Functional Characterization of the Human Multidrug Transporter, ABCG2, Expressed in Insect Cells
Özvegy, C., Litman, T., Szakács, G., Nagy, Z., Bates, S., Váradi, A., & Sarkadi, B. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5130 · Cited by 319
Mizuarai, S., Aozasa, N., & Kotani, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.11669 · Cited by 318
ABC of oral bioavailability: transporters as gatekeepers in the gut
Dietrich, C. G., Geier, A., & Oude Elferink, R. P. J. (2003) · Gut · doi:10.1136/gut.52.12.1788 · Cited by 317
Understanding cancer and the anticancer activities of naphthoquinones – a review
Wellington, K. W. (2015) · RSC Advances · doi:10.1039/c4ra13547d · Cited by 316
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future
Cole, S. P. C. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135959 · Cited by 309
Ma, J., Dong, C., & Ji, C. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.18 · Cited by 303
ABC-transporters: implications on drug resistance from microorganisms to human cancers
Lage, H. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00203-6 · Cited by 298
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
de Bruin, M., Miyake, K., Litman, T., Robey, R., & Bates, S. E. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00182-2 · Cited by 298
Budhu, A. S., & Noy, N. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2632-2641.2002 · Cited by 296
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant
Hu, L., McArthur, C., & Jaffe, R. B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605626 · Cited by 296
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
Agarwal, S., Sane, R., Oberoi, R., Ohlfest, J. R., & Elmquist, W. F. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001888 · Cited by 292
Kage, K., Tsukahara, S., Sugiyama, T., Asada, S., Ishikawa, E., Tsuruo, T., & Sugimoto, Y. (2002) · International Journal of Cancer · doi:10.1002/ijc.10100 · Cited by 291
Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
Bhowmik, A., Khan, R., & Ghosh, M. K. (2015) · BioMed Research International · doi:10.1155/2015/320941 · Cited by 291
Drug transporters in the human blood‐placental barrier
Vähäkangas, K., & Myllynen, P. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00336.x · Cited by 289
Chasman, D. I., Giulianini, F., MacFadyen, J., Barratt, B. J., Nyberg, F., & Ridker, P. M. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.961144 · Cited by 285
ABCG2 – a transporter for all seasons
Sarkadi, B., Özvegy-Laczka, C., Német, K., & Váradi, A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.03.123 · Cited by 282
Imai, Y., Tsukahara, S., Asada, S., & Sugimoto, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0078 · Cited by 280
Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
Ni, Z., Bikadi, Z., F. Rosenberg, M., & Mao, Q. (2010) · Current Drug Metabolism · doi:10.2174/138920010792927325 · Cited by 277
Diestra, J. E., Scheffer, G. L., Català, I., Maliepaard, M., Schellens, J. H. M., Scheper, R. J., Germà‐Lluch, J. R., & Izquierdo, M. A. (2002) · The Journal of Pathology · doi:10.1002/path.1203 · Cited by 275
Side population cells and Bcrp1 expression in lung
Summer, R., Kotton, D. N., Sun, X., Ma, B., Fitzsimmons, K., & Fine, A. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00009.2003 · Cited by 275
Flavonoid–drug interactions: Effects of flavonoids on ABC transporters
Morris, M. E., & Zhang, S. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.003 · Cited by 273
Cancer stem cells: implications for the progression and treatment of metastatic disease
Croker, A. K., & Allan, A. L. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00211.x · Cited by 273
Zamber, C. P., Lamba, J. K., Yasuda, K., Farnum, J., Thummel, K., Schuetz, J. D., & Schuetz, E. G. (2003) · Pharmacogenetics · doi:10.1097/00008571-200301000-00004 · Cited by 272
Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Agarwal, S., M.S. Hartz, A., F. Elmquist, W., & Bauer, B. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440186 · Cited by 272
de Vries, N. A., Zhao, J., Kroon, E., Buckle, T., Beijnen, J. H., & van Tellingen, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1335 · Cited by 270
FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA
Kobayashi, D., Ieiri, I., Hirota, T., Takane, H., Maegawa, S., Kigawa, J., Suzuki, H., Nanba, E., Oshimura, M., Terakawa, N., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001628 · Cited by 268
Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2
Xu, J., Liu, Y., Yang, Y., Bates, S., & Zhang, J.-T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310785200 · Cited by 267
The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts
Chandra, P., & Brouwer, K. L. R. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026420.79421.8f · Cited by 266
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer
Tang, Y., Wang, Y., Kiani, M. F., & Wang, B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.05.012 · Cited by 265
Role of ABCG1 and other ABCG family members in lipid metabolism
Schmitz, G., Langmann, T., & Heimerl, S. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32205-7 · Cited by 265
Functional Analysis of SNPs Variants of BCRP/ABCG2
Kondo, C., Suzuki, H., Itoda, M., Ozawa, S., Sawada, J.-I., Kobayashi, D., Ieiri, I., Mine, K., Ohtsubo, K., & Sugiyama, Y. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000045245.21637.d4 · Cited by 264
The role of transporters in cellular heme and porphyrin homeostasis
KRISHNAMURTHY, P., XIE, T., & SCHUETZ, J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.02.001 · Cited by 260
Multidrug resistance: Physiological principles and nanomedical solutions
Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.018 · Cited by 259
Drug resistance: Still a daunting challenge to the successful treatment of AML
Shaffer, B. C., Gillet, J.-P., Patel, C., Baer, M. R., Bates, S. E., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.001 · Cited by 259
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
Wu, C., Calcagno, A. M., & Ambudkar, S. V. (2008) · Current Molecular Pharmacology · doi:10.2174/1874-470210801020093 · Cited by 259
Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)
Zelcer, N., Saeki, T., Reid, G., Beijnen, J. H., & Borst, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107041200 · Cited by 258
Mitoxantrone, More than Just Another Topoisomerase II Poison
Evison, B. J., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21364 · Cited by 253
Zhao, R., & Goldman, I. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206946 · Cited by 253
Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges
Shukla, S., Wu, C.-P., & Ambudkar, S. V. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.205 · Cited by 253
Frank, N. Y., Pendse, S. S., Lapchak, P. H., Margaryan, A., Shlain, D., Doeing, C., Sayegh, M. H., & Frank, M. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308700200 · Cited by 242
Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells
Kawabata, S., Oka, M., Shiozawa, K., Tsukamoto, K., Nakatomi, K., Soda, H., Fukuda, M., Ikegami, Y., Sugahara, K., Yamada, Y., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4267 · Cited by 242
Self-citationDiflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1
SPARREBOOM, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.003 · Cited by 241
“-187) 44 (15-187) 25 (17-53) 17) 29 (12-117) 32 (7-46) -2354) 175 (71-2354) 122 (87-457) -801) 145 (20-801) 23 (12-217) 2) 7 (3-22) 9 (4-12) -136) 79 (53-136) 95 (70-109) -48) 41 (29-48) 42 (38-45) -87) 75 (60-87) 68 (66-83)”
Role of ATP‐binding cassette transporters in brain lipid transport and neurological disease
Kim, W. S., Weickert, C. S., & Garner, B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05099.x · Cited by 238
“ABCG2 was originally identified in a multidrug-resistant breast cancer cell line and called breast cancer resistance protein (Doyle et al. 1998).”
BackgroundThe role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis
Assaraf, Y. G. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.09.001 · Cited by 235
Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells
Huang, Y., & Sadée, W. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.032 · Cited by 230
Wang, R. B., Kuo, C. L., Lien, L. L., & Lien, E. J. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00487.x · Cited by 225
Pluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Ee, P. L. R., Kamalakaran, S., Tonetti, D., He, X., Ross, D. D., & Beck, W. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3583 · Cited by 217
“It was initially found to be associated with mitoxantrone resistance (2, 3, 5, 7) and later found to confer resistance to other drugs such as topotecan, SN-38, anthracyclines, and flavopiridol (4, 7–9).”
BackgroundSelf-citationGupta, A., Zhang, Y., Unadkat, J. D., & Mao, Q. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065342 · Cited by 216
“The human breast cancer resistance protein (BCRP/MXR/ ABCG2) is a relatively new ATP-binding cassette transporter originally cloned from drug-selected human cancer cell lines and human placenta (Allikmets et al., 1998; Doyle et al., 1998; Miyake et al., 1999).”
BackgroundLiu, H., Liu, Y., & Zhang, J.-T. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0445 · Cited by 216
“thought to be the mechanism of drug resistance in this cell line (3, 4).”
BackgroundMimeault, M., Hauke, R., Mehta, P. P., & Batra, S. K. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00088.x · Cited by 212
Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
K. Tiwari, A., Sodani, K., Dai, C.-L., R. Ashby, C., & Chen, Z.-S. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111795164048 · Cited by 211
“Three different research groups almost simultaneously identified the ABCG2/BCRP transporter about 12 years ago [41-43].”
BackgroundMolecular Pharmacology of ABCG2 and Its Role in Chemoresistance
Stacy, A. E., Jansson, P. J., & Richardson, D. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.088609 · Cited by 210
“Additionally, ABCG2 is unusual among ABC transporters in that it is a “half transporter” (Doyle et al., 1998).”
BackgroundInfluentialMRP6 (ABCC6) Detection in Normal Human Tissues and Tumors
Scheffer, G. L., Hu, X., Pijnenborg, A. C. L. M., Wijnholds, J., Bergen, A. A. B., & Scheper, R. J. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780444 · Cited by 204
“Closely related proteins such as MDR1 P-glycoprotein (P-gp, ABCB1, reviewed by Ambudkar et al, 1999), breast cancer resistance protein (BCRP, ABCG2; Doyle et al, 1998), and MRP1, -2, and -3 (ABCC1–3) are established MDR transporters.”
BackgroundSzakács, G., Hall, M. D., Gottesman, M. M., Boumendjel, A., Kachadourian, R., Day, B. J., Baubichon-Cortay, H., & Di Pietro, A. (2014) · Chemical Reviews · doi:10.1021/cr4006236 · Cited by 203
The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance
Januchowski, R., Wojtowicz, K., & Zabel, M. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.04.005 · Cited by 202
Intestinal efflux transporters and drug absorption
Murakami, T., & Takano, M. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.923 · Cited by 201
“3 BCRP BCRP ( ABCG2 ) was initially isolated from a doxorubicinresistant MCF-7/AdrVp breast cancer cell line [42] .”
BackgroundATP-binding cassette (ABC) transporters in normal and pathological lung
van der Deen, M., de Vries, E. G., Timens, W., Scheper, R. J., Timmer-Bosscha, H., & Postma, D. S. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-59 · Cited by 198
Braun, T., Challis, J. R., Newnham, J. P., & Sloboda, D. M. (2013) · Endocrine Reviews · doi:10.1210/er.2013-1012 · Cited by 196
Subcellular Localization and Activity of Multidrug Resistance Proteins
Rajagopal, A., & Simon, S. M. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0704 · Cited by 190
“The BCRP cDNA was a generous gift of Doug Ross (University of Maryland, Baltimore, MD) (Doyle et al., 1998); it was subcloned into the EGFPc1 plasmid (BD Biosciences Clontech) between the EcoRI and XhoI sites.”
BackgroundMethodABCG2 expression, function, and promoter methylation in human multiple myeloma
Turner, J. G., Gump, J. L., Zhang, C., Cook, J. M., Marchion, D., Hazlehurst, L., Munster, P., Schell, M. J., Dalton, W. S., & Sullivan, D. M. (2006) · Blood · doi:10.1182/blood-2005-10-009084 · Cited by 189
Xie, Y., Xu, K., Linn, D. E., Yang, X., Guo, Z., Shimelis, H., Nakanishi, T., Ross, D. D., Chen, H., Fazli, L., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707773200 · Cited by 189
Self-citationNakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5850 · Cited by 189
Overview of Tumor Cell Chemoresistance Mechanisms
Gatti, L., & Zunino, F. (2005) · Chemosensitivity · doi:10.1385/1-59259-889-7:127 · Cited by 179
Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Gonçalves, P., & Martel, F. (2013) · Current Drug Metabolism · doi:10.2174/1389200211314090006 · Cited by 179
Nakamura, Y., Oka, M., Soda, H., Shiozawa, K., Yoshikawa, M., Itoh, A., Ikegami, Y., Tsurutani, J., Nakatomi, K., Kitazaki, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-2417 · Cited by 177
“The breast cancer resistance protein (BCRP/ ABCG2) of an ATP-binding cassette half-transporter was isolated from atypical multidrug-resistant MCF-7 human breast cancer cells selected with doxorubicin and verapamil (17).”
Blood−brain barrier transporters and response to CNS-active drugs
Urquhart, B. L., & Kim, R. B. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0714-8 · Cited by 174
“BCRP was originally identified in a breast cancer cell line that exhibited resistance to anthracyclines [24].”
BackgroundNatural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer
Joshi, P., Vishwakarma, R. A., & Bharate, S. B. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.047 · Cited by 174
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z.-S., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 168
“, 2009; Kruh and Belinsky, 2003) and ABCG2 (BCRP/MXR/ABCP) (Allikmets et al., 1998; Doyle et al., 1998; Miyake et al., 1999).”
BackgroundNoguchi, K., Katayama, K., & Sugimoto, Y. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s38295 · Cited by 167
Role of ABC transporters in cancer chemotherapy
Sun, Y.-L., Patel, A., Kumar, P., & Chen, Z.-S. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10466 · Cited by 166
Zaher, H., Khan, A. A., Palandra, J., Brayman, T. G., Yu, L., & Ware, J. A. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050113v · Cited by 162
ABC transporters in fish species: a review
Ferreira, M., Costa, J., & Reis-Henriques, M. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00266 · Cited by 160
“Several transporters have been pointed out as relevant in the ecotoxicological context associated to the transport of xenobiotics, such as P-glycoproteins (Pgps), multidrug-resistance-associated proteins (MRPs 1-5) and breast cancer resistance associated protein (BCRP).”
BackgroundJanvilisri, T., Venter, H., Shahi, S., Reuter, G., Balakrishnan, L., & van Veen, H. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301358200 · Cited by 158
Zhou, S., Zong, Y., Ney, P. A., Nair, G., Stewart, C. F., & Sorrentino, B. P. (2005) · Blood · doi:10.1182/blood-2004-04-1566 · Cited by 157
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152
The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids
Holland, M. L., Lau, D. T. T., Allen, J. D., & Arnold, J. C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707467 · Cited by 150
“In vitro, ABCG2 confers resistance to several clinically employed anticancer drugs, including mitoxantrone, bisantrene, topotecan, SN-38, 9-aminocamptothecin and flavopiridol (Doyle et al., 1998; Maliepaard et al., 1999; Kawabata et al., 2001; Robey et al., 2001).”
BackgroundInfluentialTamura, A., Watanabe, M., Saito, H., Nakagawa, H., Kamachi, T., Okura, I., & Ishikawa, T. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023556 · Cited by 141
“Human ABCG2 is a member of the ABC transporter family (Allikmets et al., 1998; Doyle et al., 1998; Miyake et al., 1999).”
BackgroundKobuchi, H., Moriya, K., Ogino, T., Fujita, H., Inoue, K., Shuin, T., Yasuda, T., Utsumi, K., & Utsumi, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050082 · Cited by 137
“ABCG2, also called breast cancer resistant protein, was first discovered in doxorubicin-resistant breast cancer cells [15], and it predominantly localizes to the plasma membrane [16].”
BackgroundThe Roles of MicroRNAs in Breast Cancer
Takahashi, R.-U., Miyazaki, H., & Ochiya, T. (2015) · Cancers · doi:10.3390/cancers7020598 · Cited by 116
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2
To, K. K. W., Robey, R. W., Knutsen, T., Zhan, Z., Ried, T., & Bates, S. E. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0292 · Cited by 112
Saito, H., Hirano, H., Nakagawa, H., Fukami, T., Oosumi, K., Murakami, K., Kimura, H., Kouchi, T., Konomi, M., Tao, E., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099036 · Cited by 92
“Human ABCG2 (ABCP/BCRP/MXR) belongs to the ABC transporter family (Allikmets et al., 1998; Doyle et al., 1998; Miyake et al., 1999) and transports a wide variety of compounds, including cytotoxic agents (mitoxantrone, topotecan, flavopiridol, and methotrexate) (Maliepaard et al., 1999; Jonker et…”
BackgroundKemp, S., & Wanders, R. J. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.10.001 · Cited by 82
“ABCG2 was originally identiWed as a gene over-expressed in several multi-drug resistant cell lines and the encoded protein plays a role in exporting a wide variety of compounds out of the cell [25].”
BackgroundTamura, A., Onishi, Y., An, R., Koshiba, S., Wakabayashi, K., Hoshijima, K., Priebe, W., Yoshida, T., Kometani, S., Matsubara, T., et al. (2007) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.22.428 · Cited by 72
Human ABC Transporter ABCG2 in Xenobiotic Protection and Redox Biology
Wakabayashi, K., Tamura, A., Saito, H., Onishi, Y., & Ishikawa, T. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600727947 · Cited by 66
“Human ABCG2 was discovered in doxorubicin-resistant breast cancer cells (Doyle et al., 1998) and named breast cancer-resistant protein (BCRP).”
BackgroundChaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166967 · Cited by 62
A Structure-Based View on ABC-Transporter Linked to Multidrug Resistance
(2023) · doi:10.3390/molecules28020495 · Cited by 48
Wu, D., Wang, C., Yang, J., Wang, H., Han, H., Zhang, A., Yang, Y., & Li, Q. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00702 · Cited by 45
Differential Sensitivity in Cell Lines to Photodynamic Therapy in Combination with ABCG2 Inhibition
Barron, G. A., Moseley, H., & Woods, J. A. (2013) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/j.jphotobiol.2013.07.003 · Cited by 40
Ishikawa, T., Takahashi, K., Ikeda, N., Kajimoto, Y., Hagiya, Y., Ogura, S.-I., Miyatake, S.-I., & Kuroiwa, T. (2011) · Pharmaceutics · doi:10.3390/pharmaceutics3030615 · Cited by 34
Metadata
- Authors
- Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-12-22
- Volume
- 95
- Issue
- 26
- Pages
- 15665-15670
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2142024216
- Cited by
- 2,322
- References
- 16
- FWCI
- 14.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.